12:00 AM
 | 
Feb 11, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Biotest sales and marketing update

Biotest's Biotest Pharmaceuticals Corp. subsidiary launched IV Bivigam 10% human immune globulin in U.S. to treat primary immune deficiency disorders. The wholesale acquisition cost of the polyspecific IV...

Read the full 129 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >